To provide a novel agent for ameliorating a skin symptom such as pigmented macules or ephelides, a novel hair growth agent, and a novel slimming agent. The agent for ameliorating a skin symptom, the hair growth agent, or the slimming agent contains a dopamine agonist as an active ingredient, in which the skin symptom is selected from pigmented macules, periorbital dark circles, darkish skin, black darkish skin, moles, ephelides, birth marks, and seborrheic keratosis.
